Tecentriq and Avastin combination meets primary endpoints in Phase III IMpower150 study for non squamous NSCLC.- Genentech/Roche

Genentech, a member of the Roche Group announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel. A survival benefit was observed across key subgroups, including those with varying levels of PD-L1 expression.

Safety for the Tecentriq and Avastin plus carboplatin and paclitaxel combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combinations. These data will be presented at an upcoming oncology congress. At this interim analysis, the study found that substituting Avastin with Tecentriq in the combination with carboplatin and paclitaxel did not show a statistically significant OS benefit in people with advanced NSCLC compared to a combination of Avastin plus carboplatin and paclitaxel.

The study will continue as planned to the final analysis. Safety in the Tecentriq plus carboplatin and paclitaxel arm appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination.

Previously reported results from the IMpower150 study showed that the combination of Tecentriq and Avastin plus carboplatin and paclitaxel reduced the risk of disease worsening or death (progression-free survival; PFS), a co-primary endpoint, by 38 percent (HR=0.62; p<0.0001, 95 percent ci: 0.52-0.74 compared to avastin plus carboplatin and paclitaxel in the first-line treatment of people with advanced non-squamous nsclc. this pfs benefit was observed across key subgroups including those with varying levels of pd-l1 expression. impower150 is one of eight phase iii lung cancer studies underway evaluating tecentriq alone or in combination with other medicines. following the positive impower150 and impower131 studies three more phase iii lung cancer studies are expected to report this year.>